MedTrace Logo

Prevention of West Syndrome With Low-dose Adrenocorticotropin Hormone (ACTH)

NCT01367964 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2018-11-16

No results posted yet for this study

Summary

West syndrome (WS) is a specific type of epilepsy (or seizure disorder) that has three features: infantile spasms (type of seizure), loss of milestones, and a specific pattern on electroencephalogram (EEG or brain wave test) called hypsarhythmia. The purpose of this study is to detect pre-hypsarhythmia in infants at high-risk for WS and determine whether treatment with ACTH will prevent WS.

Conditions

  • West Syndrome

Interventions

DRUG

adrenocorticotropin hormone

ACTH 16 units intramuscular injection once daily for 2 weeks

Sponsors & Collaborators

  • Thrasher Research Fund

    collaborator OTHER

  • Ann & Robert H Lurie Children's Hospital of Chicago

    lead OTHER

Principal Investigators

  • John J. Millichap, MD · Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine

  • Sookyong Koh, MD, PhD · Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine

  • Doulgas R Nordli, Jr, MD · Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Months
Max Age
12 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01367964 on ClinicalTrials.gov